Prostate Cancer Reports

Volume 3 Number 4
April 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 4, April


Case reports
Detection, diagnosis and evaluation
Etiology and pathogenesis
Integrative medicine
Overall management
Prognosis and outcome


Bourlon MT, Glodé LM, Crawford ED.
Base of the skull metastases in metastatic castration-resistant prostate cancer.
Oncology (Williston Park). 2014 Dec 15;28(12). pii: 202937.
Abstract | Full text | Related citations


Castellucci P, Fanti S.
Prostate cancer: Identifying sites of recurrence with choline-PET-CT imaging.
Nat Rev Urol. 2014 Dec 2. doi: 10.1038/nrurol.2014.321. [Epub ahead of print]
Abstract | Related citations

Garcia JR, Romera N, Cozar M, Soler M, Moragas M, Escobar M.
11C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Actas Urol Esp. 2014 Nov 15. pii: S0210-4806(14)00373-8. doi: 10.1016/j.acuro.2014.10.004. [Epub ahead of print]
Abstract | Related citations

Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, Alvarez-Moro FJ, Moragas M, Riera E.
[Diagnostic performance of bone scintigraphy and 11C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer.]
Rev Esp Med Nucl Imagen Mol. 2014 Nov 15. pii: S2253-654X(14)00170-X. doi: 10.1016/j.remn.2014.08.001. [Epub ahead of print]
Abstract | Related citations

Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, Omoumi P, Vande Berg BC, Lecouvet FE.
Whole-Body 3D T1-weighted MR Imaging in Patients with Prostate Cancer: Feasibility and Evaluation in Screening for Metastatic Disease.
Radiology. 2014 Dec 15:141242. [Epub ahead of print]
Abstract | Related citations

Prostate-specific antigen

Seikkula H, Syvänen KT, Kurki S, Mirtti T, Taimen P, Laato M, Boström PJ.
Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy.
Urol Oncol. 2014 Nov 18. pii: S1078-1439(14)00353-6. doi: 10.1016/j.urolonc.2014.10.010. [Epub ahead of print]
Abstract | Related citations


Ceder JA.
Targeting the Mechanisms of Progression in Castration-resistant Prostate Cancer.
Eur Urol. 2014 Nov 21. pii: S0302-2838(14)01198-1. doi: 10.1016/j.eururo.2014.11.024. [Epub ahead of print]
Abstract | Full text | Related citations

Kahn B, Collazo J, Kyprianou N.
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Int J Biol Sci. 2014 Jun 1;10(6):588-95. doi: 10.7150/ijbs.8671. eCollection 2014.
Abstract | Full text | Related citations

Lian F, Sharma NV, Moran JD, Moreno CS.
The biology of castration-resistant prostate cancer.
Curr Probl Cancer. 2015 Jan-Feb;39(1):17-28. doi: 10.1016/j.currproblcancer.2014.11.004. Epub 2014 Nov 25.
Abstract | Related citations


Labbé DP, Zadra G, Ebot EM, Mucci LA, Kantoff PW, Loda M, Brown M.
Role of diet in prostate cancer: the epigenetic link.
Oncogene. 2014 Dec 22. doi: 10.1038/onc.2014.422. [Epub ahead of print]
Abstract | Full text | Related citations

Pon D, Abe A, Gupta EK.
A review of statin use and prostate cancer.
Curr Atheroscler Rep. 2015 Feb;17(2):474. doi: 10.1007/s11883-014-0474-5. Epub 2014 Nov 11.
Abstract | Full text | Related citations


Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ.
ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer.
Oncology (Williston Park). 2014 Dec 15;28(12). pii: 202938.
Abstract | Full text | Related citations


Biochemical recurrence

Extent of extraprostatic extension, lymph node metastasis

Ball MW, Partin AW, Epstein JI.
Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification.
Urology. 2015 Jan;85(1):161-4. doi: 10.1016/j.urology.2014.08.025. Epub 2014 Oct 18.
Abstract | Full text | Related citations

Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, Shariat SF.
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.
BJU Int. 2014 Oct;114(4):503-10. doi: 10.1111/bju.12342. Epub 2014 Apr 3.
Abstract | Related citations

Gleason score

Lucca I, Shariat SF, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatte T.
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model.
Urol Oncol. 2014 Oct 23. pii: S1078-1439(14)00289-0. doi: 10.1016/j.urolonc.2014.08.011. [Epub ahead of print]
Abstract | Related citations

Positive surgical margins

Dev HS, Wiklund P, Patel V, Parashar D, Palmer K, Nyberg T, Skarecky D, Neal DE, Ahlering T, Sooriakumaran P.
Surgical margin length and location affect recurrence rates after robotic prostatectomy.
Urol Oncol. 2014 Dec 12. pii: S1078-1439(14)00392-5. doi: 10.1016/j.urolonc.2014.11.005. [Epub ahead of print]
Abstract | Related citations


Biochemical recurrence

D'Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, Fiore M, Gallucci M, Maini CL, Trodella L.
¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):296-302. doi: 10.1016/j.ijrobp.2014.05.050. Epub 2014 Jul 29.
Abstract | Related citations

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G.
A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802.
Eur Urol. 2014 Dec 18. pii: S0302-2838(14)01265-2. doi: 10.1016/j.eururo.2014.12.010. [Epub ahead of print]
Abstract | Related citations

Castration-resistant prostate cancer

Anantharaman A, Friedlander TW.
The Double-Edged Sword of ADT: Emerging Evidence of Cardiovascular, Pulmonary, and Renal Risks
Oncology (Williston Park). 2015 Jan
Abstract | Full text | Related citations

Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E.
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Eur Urol. 2014 Oct 25. pii: S0302-2838(14)01022-7. doi: 10.1016/j.eururo.2014.10.014. [Epub ahead of print]
Abstract | Related citations

Crawford ED, Moul JW.
ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury.
Oncology (Williston Park). 2015 Jan 15;29(1). pii: 203351.
Abstract | Full text | Related citations

Frieling JS, Basanta D, Lynch CC.
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
Cancer Control. 2015 Jan;22(1):109-20.
Abstract | Full text | Related citations

Testosterone replacement

Anna Azvolinsky, PhD
Anna Azvolinsky, PhD
Anna Azvolinsky, PhD
Azvolinsky A.
Can testosterone treat prostate cancer?
Abstract | Full text | Related citations

Klotz L.
Testosterone therapy and prostate cancer-safety concerns are well founded.
Nat Rev Urol. 2015 Jan 7;12(1):48-54. doi: 10.1038/nrurol.2014.338.
Abstract | Related citations

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.
Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.
Abstract | Related citations

Metastatic prostate cancer

Crispen P.
Should We Perform Prostatectomy in the Face of Metastatic Prostate Cancer?
J Urol. 2014 Dec 17. pii: S0022-5347(14)05118-0. doi: 10.1016/j.juro.2014.12.066. [Epub ahead of print]
Abstract | Related citations

Neuroendocrine prostate cancer

Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.
Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Oncotarget. 2014 Dec 11. [Epub ahead of print]
Abstract | Full text | Related citations

Oligometastatic prostate cancer

Moreno A, Albiach C, Soria R, Vidal V, Gómez R, Antequera M.
Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.
Radiat Oncol. 2014 Dec 11;9(1):258. [Epub ahead of print]
Abstract | Full text | Related citations

Aoun F, Peltier A, van Velthoven R.
A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer.
Biomed Res Int. 2014;2014:501213. doi: 10.1155/2014/501213. Epub 2014 Nov 17.
Abstract | Full text | Related citations

Treatment-related complications

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis.
Eur Urol. 2014 Dec 4. pii: S0302-2838(14)01222-6. doi: 10.1016/j.eururo.2014.11.039. [Epub ahead of print]
Abstract | Full text | Related citations